BioCentury | Apr 11, 2016
Company News

Gyros, Protein Technologies deal

...biotherapeutics. Gyros’ products include its Gyrolab xP workstation. Protein’s products include its Symphony X and Sonata...
BioCentury | Oct 19, 2015
Company News

Alexza drug delivery, neurology news

...is alprazolam, a GABA receptor modulating benzodiazepine, delivered via the Staccato system inhaler. AZ-007 is zaleplon...
BioCentury | May 5, 2014
Clinical News

Lifitegrast: Phase III data

...Top-line data from the double-blind, placebo-controlled, U.S. Phase III SONATA safety trial in 332 patients with...
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

...III data 2Q14 Shire plc (LSE:SHP; NASDAQ:SHPG) Lifitegrast Dry eye disease (keratoconjunctivitis sicca) Ph III SONATA...
BioCentury | Dec 9, 2013
Clinical News

Lifitegrast: Phase III data

...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III SONATA...
BioCentury | Apr 1, 2013
Company News

SARcode, Shire deal

...days. The company is also evaluating the long-term safety of lifitegrast in the Phase III SONATA...
...to FDA for lifitegrast to treat dry eye disease in 2H14 and that data from SONATA...
BioCentury | Jan 14, 2013
Clinical News

Lifitegrast: Phase III started

...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III SONATA...
BioCentury | Oct 29, 2012
Clinical News

Lifitegrast: Phase III data

...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III SONATA...
BioCentury | Oct 24, 2012
Clinical News

SARcode reports Phase III data for dry eye treatment

...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III SONATA...
BioCentury | Jun 20, 2011
Clinical News

SKP-1041: Phase II data

...Inc. , Bedminster, N.J. Product: SKP-1041 Business: Neurology Molecular target: NA Description: Delayed-release formulation of zaleplon...
Items per page:
1 - 10 of 51